Symbol
| GPC3
| contributors: mct - updated : 25-10-2016
|
HGNC name
| glypican 3
|
HGNC id
| 4451
|
corresponding disease(s)
|
SGBS
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --low
|  
|
in mesothelioma, breast and ovarian cancer | tumoral
|  
|  
| --over
|  
|
in hepatocellular carcinoma (HCC), neuroblastoma and Wilm's tumor cells | tumoral
|  
|  
| --low
|  
|
in intrahepatic chanlangiocarcinoma | |
Variant & Polymorphism
|
| |
Candidate gene
| specific immunomarker for HCC that can be used to distinguish HCC from benign hepatocellular mass lesions, particularly hepatocellular adenoma , but combination of AFP and GPC3 can elevate the sensitivity of diagnosis |
|
may have future application as a biomarker for rhabdomyosarcomas |
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | digestive | liver | |
anti-glypican 3 antibody against the C-terminal 30-kDa fragment such as GC33 are useful in therapy targeting hepatocellular carcinoma | cancer | muscle | | |
may be a therapeutic target in rhabdomyosarcomas (RMS), the most common paediatric soft tissue sarcomas |
| | |
| Gpc3-deficient mice display a high incidence of congenital cardiac malformations like ventricular septal defects, common atrioventricular canal and double outlet right ventricle |